Covered recipient · General Payments record
CAROLINA CASTANO
Physician Assistants & Advanced Practice Nursing Providers Physician Assistant Medical
General Payments · PY2021–2024
$1,683.89
- Reported across 86 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $580.06 | 34 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $169.12 | 17 |
| Lilly USA, LLC | $109.98 | 5 |
| ABBVIE INC. | $56.50 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $47.22 | 2 |
| DEXCOM, INC. | $35.47 | 1 |
| Azurity Pharmaceuticals, Inc. | $31.82 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $26.22 | 1 |
| Corcept Therapeutics | $24.04 | 1 |
| Novo Nordisk AS | $23.83 | 1 |
| CeQur Corporation | $21.77 | 1 |
| GlaxoSmithKline, LLC. | $19.36 | 1 |
| Averitas Pharma Inc. | $14.73 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (34)
Sorted by paying entity, then date · as published by CMS
Program year 2024 202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $26.29 | 06/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106892095 | CMS |
| ABBVIE INC. | $30.21 | 07/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106892097 | CMS |
| Amgen Inc. | $7.89 | 01/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117522357 | CMS |
| Amgen Inc. | $7.02 | 02/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115484979 | CMS |
| Amgen Inc. | $7.12 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117522359 | CMS |
| Amgen Inc. | $8.16 | 03/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117522361 | CMS |
| Amgen Inc. | $6.71 | 03/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115484984 | CMS |
| Amgen Inc. | $8.15 | 04/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117522363 | CMS |
| Amgen Inc. | $11.63 | 05/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117522365 | CMS |
| Amgen Inc. | $6.95 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117522367 | CMS |
| Amgen Inc. | $12.11 | 07/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117522369 | CMS |
| Amgen Inc. | $13.40 | 08/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115484990 | CMS |
| Amgen Inc. | $11.88 | 09/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117522371 | CMS |
| Amgen Inc. | $9.47 | 10/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117522373 | CMS |
| Amgen Inc. | $9.11 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115484996 | CMS |
| Amgen Inc. | $11.28 | 10/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117522375 | CMS |
| Amgen Inc. | $4.96 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117522377 | CMS |
| Amgen Inc. | $16.64 | 12/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115485002 | CMS |
| Amgen Inc. | $16.64 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115485008 | CMS |
| Averitas Pharma Inc. | $14.73 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133455070 | CMS |
| Azurity Pharmaceuticals, Inc. | $31.82 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134016111 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $26.22 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086338367 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $17.73 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118062165 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $29.49 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118062167 | CMS |
| CeQur Corporation | $21.77 | 04/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1099649959 | CMS |
| Corcept Therapeutics | $24.04 | 09/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117762947 | CMS |
| Dexcom, Inc. | $35.47 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153353264 | CMS |
| GlaxoSmithKline, LLC. | $19.36 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116651147 | CMS |
| Lilly USA, LLC | $24.71 | 01/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135577026 | CMS |
| Lilly USA, LLC | $20.17 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135615517 | CMS |
| Lilly USA, LLC | $23.19 | 03/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135577542 | CMS |
| Lilly USA, LLC | $16.34 | 03/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135589767 | CMS |
| Lilly USA, LLC | $25.57 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135589769 | CMS |
| Novo Nordisk Inc | $23.83 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100480635 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.